151 related items for PubMed ID: 14974908
1. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
McKenzie J, Jaap AJ, Gallacher S, Kelly A, Crawford L, Greer IA, Rumley A, Petrie JR, Lowe GD, Paterson K, Sattar N.
Clin Endocrinol (Oxf); 2003 Dec; 59(6):682-9. PubMed ID: 14974908
[Abstract] [Full Text] [Related]
2. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial.
McKenzie J, Fisher BM, Jaap AJ, Stanley A, Paterson K, Sattar N.
Clin Endocrinol (Oxf); 2006 Jul; 65(1):40-4. PubMed ID: 16817817
[Abstract] [Full Text] [Related]
3. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.
Kwok S, Selby PL, McElduff P, Laing I, Mackness B, Mackness MI, Prais H, Morgan J, Yates AP, Durrington PN, Sci FM.
Clin Endocrinol (Oxf); 2004 Dec; 61(6):760-7. PubMed ID: 15579192
[Abstract] [Full Text] [Related]
4. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
Perera M, Sattar N, Petrie JR, Hillier C, Small M, Connell JM, Lowe GD, Lumsden MA.
J Clin Endocrinol Metab; 2001 Mar; 86(3):1140-3. PubMed ID: 11238498
[Abstract] [Full Text] [Related]
5. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes.
Kernohan AF, Sattar N, Hilditch T, Cleland SJ, Small M, Lumsden MA, Connell JM, Petrie JR.
Clin Endocrinol (Oxf); 2007 Jan; 66(1):27-34. PubMed ID: 17201798
[Abstract] [Full Text] [Related]
6. The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes.
Thunell L, Andersson B, Glassell M, Mattsson LA.
Maturitas; 2006 Mar 20; 53(4):430-8. PubMed ID: 16198072
[Abstract] [Full Text] [Related]
7. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
Menopause; 2006 Mar 20; 13(4):643-50. PubMed ID: 16837886
[Abstract] [Full Text] [Related]
8. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
Eilertsen AL, Høibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM.
Maturitas; 2005 Oct 16; 52(2):111-8. PubMed ID: 16186073
[Abstract] [Full Text] [Related]
9. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H.
Thromb Haemost; 2001 Apr 16; 85(4):619-25. PubMed ID: 11341495
[Abstract] [Full Text] [Related]
10.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
14. Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control.
Aguilar-Salinas CA, Arita Melzer O, Sauque Reyna L, Lopez A, Velasco Perez ML, Guillen LE, Gomez Perez FJ, Rull Rodrigo JA.
Isr Med Assoc J; 2001 Feb 16; 3(2):137-43. PubMed ID: 11344825
[Abstract] [Full Text] [Related]
15. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
Brynhildsen J, Hammar M.
Maturitas; 2005 Apr 11; 50(4):344-52. PubMed ID: 15780536
[Abstract] [Full Text] [Related]
16. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H, Odabasi AR, Demircan S, Köseoğlu K, Kizilkaya K, Onur E.
Gynecol Endocrinol; 2007 Feb 11; 23(2):99-104. PubMed ID: 17454160
[Abstract] [Full Text] [Related]
17. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
Peverill RE, Teede HJ, Smolich JJ, Malan E, Kotsopoulos D, Tipping PG, McGrath BP.
Clin Sci (Lond); 2001 Jul 11; 101(1):93-9. PubMed ID: 11410120
[Abstract] [Full Text] [Related]
18. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
Skouby SO, Sidelmann JJ, Nilas L, Gram J, Jespersen J.
Climacteric; 2008 Jul 11; 11(6):489-97. PubMed ID: 18991076
[Abstract] [Full Text] [Related]
19.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
20. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
Clin Ther; 2004 Oct 11; 26(10):1599-607. PubMed ID: 15598476
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
